TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
PLAINSBORO, N.J., Oct. 06, 2017 -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced the launch of Revize™ / Revize-X™ Collagen Matrix, its latest offering in tissue-building solutions for plastic and reconstructive surgery. Revize and Revize-X are derived from fetal bovine dermis, which is rich in Type III collagen. Revize-X is an expandable matrix that provides up to twice the initial coverage area once hydrated and fully expanded. It features a meshing pattern which allows for vascular ingrowth and increased conformability.
“The Revize and Revize-X products provide new, innovative solutions to plastic and reconstructive surgeons for use in their private practices. Our entry into this space will provide surgeons with leading edge technology for patients undergoing cosmetic revisionary procedures,” said Robert T. Davis, Jr., corporate vice president and president, Orthopedics and Tissue Technologies.
About Revize and Revize-X
Revize / Revize-X is intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes. Revize / Revize-X is specifically indicated for plastic and reconstructive surgery.
About Integra
Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, and orthopedics and tissue technologies. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Company
Investors:
Michael Beaulieu
+ 609 750 2827
[email protected]
Media:
Laurene Isip (U.S.)
+ 609 750 7984
[email protected]
